Loss of EphB6 expression in metastatic melanoma

  • Authors:
    • Christian Hafner
    • Frauke Bataille
    • Stefanie Meyer
    • Bernd Becker
    • Alexander Roesch
    • Michael Landthaler
    • Thomas Vogt
  • View Affiliations

  • Published online on: December 1, 2003     https://doi.org/10.3892/ijo.23.6.1553
  • Pages: 1553-1559
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Overexpression of various members of the Eph receptor tyrosine kinases and their ephrin ligands has been frequently reported in cancer. In contrast, a loss of EphB6 gene expression has been correlated with a poor prognosis in human neuroblastoma, suggesting a distinct role for this receptor compared to other family members. More recently, an important role of EphB6 signalling in T-cells has been described, suggesting possibly deleterious immunologic effects of a loss of EphB6 in cancer progression. We investigated the expression of EphB6 in melanocytic tumors. EphB6 mRNA of 22 microdissected tissues (7 benign nevi, 7 melanomas, 8 metastases) and 10 different cell lines (normal melanocytes, non-metastatic/metastatic melanoma cell lines) were measured by quantitative real-time RT-PCR. For visualization of EphB6 protein expression, immunohistochemistry of 32 melanocytic lesions were performed. On the mRNA level, the benign nevi revealed the highest EphB6 expression (mean = 1.43), while melanomas (mean = 0.63) and metastases (mean = 0.08; p=0.001) displayed a progressive and significant reduction of EphB6 expression. Accordingly, established melanoma cell lines with metastatic potential showed low EphB6 expression in comparison to normal melanocytes and to most of the melanoma cell lines. Immunohistochemistry revealed homogeneous staining in common nevi, whereas in malignant melanomas and metastases a heterogeneously positive to completely negative EphB6 staining was observed. Remarkably, Spitz nevi stained similarly to ordinary melanocytic nevi. Taken together, we show that melanoma progression to metastatic disease is associated with a significant reduction of EphB6 gene expression which may have considerable consequences for the prognosis of malignant melanoma patients and possible gene-therapeutic approaches.

Related Articles

Journal Cover

December 2003
Volume 23 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hafner C, Bataille F, Meyer S, Becker B, Roesch A, Landthaler M and Vogt T: Loss of EphB6 expression in metastatic melanoma. Int J Oncol 23: 1553-1559, 2003
APA
Hafner, C., Bataille, F., Meyer, S., Becker, B., Roesch, A., Landthaler, M., & Vogt, T. (2003). Loss of EphB6 expression in metastatic melanoma. International Journal of Oncology, 23, 1553-1559. https://doi.org/10.3892/ijo.23.6.1553
MLA
Hafner, C., Bataille, F., Meyer, S., Becker, B., Roesch, A., Landthaler, M., Vogt, T."Loss of EphB6 expression in metastatic melanoma". International Journal of Oncology 23.6 (2003): 1553-1559.
Chicago
Hafner, C., Bataille, F., Meyer, S., Becker, B., Roesch, A., Landthaler, M., Vogt, T."Loss of EphB6 expression in metastatic melanoma". International Journal of Oncology 23, no. 6 (2003): 1553-1559. https://doi.org/10.3892/ijo.23.6.1553